


# Evaluation of antimicrobial susceptibility patterns for patients admitted from post-acute care facilities in the Philadelphia region

Sandhya Vijapurapu, PharmD<sup>1</sup>, Christina Maguire, PharmD, BCIDP<sup>2</sup>, Amanda Binkley, PharmD, BCIDP, AAHIVP<sup>2</sup>, Shawn Binkley, BS, PharmD, BCIDP<sup>3</sup>, Raymond Lamore, PharmD, BCCCP<sup>2</sup>

Children's National Hospital, Washington, DC 20010<sup>1</sup>  
 Penn Presbyterian Medical Center, University of Pennsylvania, Philadelphia, PA 19104<sup>2</sup>  
 Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA 19104<sup>3</sup>



**Penn Medicine**  
 Penn Presbyterian Medical Center

## Background

- Timely initiation of antimicrobial therapy is essential to decreasing mortality associated with bacterial infections, and antibiograms are a key tool in the determination of appropriate empiric therapy<sup>1-2</sup>
- Patients admitted from nursing homes have a higher incidence of multi-drug resistant organisms<sup>3,4</sup>
- Currently, there is a lack of published studies evaluating resistance rates for all sources of infections with direct comparison to an inpatient antibiogram
- Current antibiograms for Penn Presbyterian Medical Center (PPMC) and the Hospital of University of Pennsylvania (HUP) do not delineate between patients admitted from the community vs PACFs

## Purpose

This study aims to characterize empiric antimicrobial therapy, pathogens isolated, and susceptibility patterns for patients admitted from PACFs in the Philadelphia region.

## Objectives

- Primary objective:**  
 Characterize the antimicrobial susceptibilities of culture-proven infections for patients admitted from PACFs
- Secondary objectives:**
- Identify discordance between empiric antimicrobial selection and antimicrobial susceptibilities
  - Evaluate mortality in patients receiving inappropriate empiric antimicrobial therapy

## Methods

- Retrospective quality improvement study, August 2020 to June 2021
  - This project was reviewed and determined to qualify as quality improvement by the University of Pennsylvania's Institutional Review Board
- Inclusion criteria:** patients admitted to PPMC or HUP from a PACF with a culture proven positive culture within 72 hours of admission
- All pertinent information was obtained via the electronic medical record

## Results

### Demographics and Current Admission (n=110)


Admitting hospital – no. (%)	
PPMC	62 (56)
HUP	48 (44)
Allergies – no. (%)	
B-lactam allergies	14 (12.7)
Fluoroquinolone allergies	2 (1.8)
Sulfa and other allergies	6 (5.5)
Type of facility patient was admitted from – no. (%)	
SNF – skilled nursing facility	98 (89.1)
LTACH – long-term acute care hospital	7 (6.4)
IRF – inpatient rehabilitation facility	5 (4.5)
Patients admitted to health-system in the past 90 days – no. (%)	
	68 (61.8)
Appropriate empiric therapy – no. (%)	
	73 (66.4)
History of MDRO* – no. (%)	
	11 (10)
ID consult at the time of antibiotic initiation – no. (%)	
	8 (7.3)
In-hospital mortality – no. (%)	
Inappropriate empiric therapy (n=36)	1 (1.9)
Readmission to health-system within 30 days – no. (%)	
	33 (30)

\*Multi-drug resistant organism

### Gram-negative susceptibilities for common empiric antimicrobial therapy

Gram-negative organisms	Cefepime		Ceftriaxone		Levofloxacin		Meropenem		Piperacillin/tazobactam	
	PACF (UPHS)	Delta	PACF (UPHS)	Delta	PACF (UPHS)	Delta	PACF (UPHS)	Delta	PACF (UPHS)	Delta
<b>E. coli (n=32)</b>	65.6% (94%)	-28.4%	59.3% (92%)	-32.7%	43.8% (75%)	-31.2%	100% (99%)	1%	82.1% (97%)	-14.9%
<b>K. pneumoniae (n=19)</b>	73.7% (91%)	-17.3%	68.4% (90%)	-21.6%	73.7% (85%)	-11.3%	84.2% (98%)	-13.8%	73.7% (88%)	-14.3%
<b>P. mirabilis (n=29)</b>	82.8% (98%)	-15.2%	82.8% (98%)	-15.2%	44.8% (81%)	-36.2%	100% (100%)	0%	82.8% (98%)	-15.2%
<b>P. aeruginosa (n=17)</b>	94% (91%)	-3%	-	-	52.9% (74%)	-21.1%	64.7% (90%)	-25.3%	76.5% (89%)	-12.5%

### Source of Culture



### Gram-Positive Organisms – no. (%)


<b>Enterococcus spp.</b>	19 (17)
<i>E. faecalis</i>	12 (63)
<i>E. faecium</i> (ampicillin-R)	5 (26)
<i>E. faecium</i> (vancomycin-R)	5 (26)
<b>Staphylococcus spp.</b>	10 (9)
MRSA*	5 (50)
MSSA**	3 (30)
Coagulase-negative staphylococci	2 (20)
<b>Streptococcus spp.</b>	2 (2)

\*Methicillin-resistant *Staphylococcus aureus*

\*\*Methicillin-susceptible *Staphylococcus aureus*

## Results Continued

### Empiric Antibiotic Selection



## Discussion/Conclusion

- A clinically significant increase in antimicrobial resistance in the post-acute care patient population admitted to our institutions
- A majority of the cohort was initiated on antimicrobial therapy that included coverage of *P. aeruginosa* and/or MRSA
  - Greatest concern with the evolution of resistance, particularly ESCR-Es due to their high likelihood of phenotypic occurrence
- Notable differences in susceptibility with PACF patients vs our current antibiogram
  - Meropenem to *P. aeruginosa* (64.7% vs 90%)
  - Cefepime to *E. coli* (65.6% vs 94%)
  - Levofloxacin to *P. mirabilis* (44.8% vs 81%)
- Overall rate of gram-positive isolates was low, noting a high percentage of MRSA isolates
- Limitations
  - Inclusion of patients limited to the Philadelphia area, restricting external validity
  - Number of isolates included in analysis, requiring an expansion of time frame beyond one year
  - In alignment with health-system antibiogram reporting process, all positive isolates were included without evaluation of clinical infection
- Rates of resistance are notable and present an opportunity for optimization of prescribing practices within UPHS

## References

- Ko BS, Choi SH, Kang GH, et al. Time to antibiotics and the outcome of patients with septic shock: a propensity score analysis. *The American Journal of Medicine*. 2020; 133:485-491.
- Kumar A, Roberts D, Wood K, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med*. 2006;34:1589-96.
- Kang YS, Ryoo SR, Byun SJ, Jeong YJ, Oh JY, Yoon YS. Antimicrobial Resistance and Clinical Outcomes in Nursing Home-Acquired Pneumonia, Compared to Community-Acquired Pneumonia. *Yonsei Med J*. 2017;58(1):180-186. doi:10.3349/ymj.2017.58.1.180
- Pulcini C, Clerc-Urmes I, Attinsonon CA, Fougnot S, Thilly N. Antibiotic resistance of Enterobacteriaceae causing urinary tract infections in elderly patients living in the community and in the nursing home: a retrospective observational study. *J Antimicrob Chemother*.

Disclosure: Authors of this poster have no conflicts of interest.